文献速递心外重症与机械循环支持

Impella 5.5超过14天支持的患者结局:心源性休克工作组注册分析

Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2025-06-29

基于34个国际中心2022-2024年CSWG注册数据,927例接受Impella 5.5支持的患者中381例支持超过14天。超14天组较≤14天组更年轻、HF-CS比例更高、LVEDD更大且CKD更多,未调整生存率更高(80% vs 68%,p<0.001),桥接至心脏替代治疗率更高(58% vs 38%,p<0.001),严重不良事件发生率19.1%,75%超14天患者获 favorable 结局。

要点

  • Impella 5.5超14天支持未增加严重不良事件线性风险。
  • 超14天组桥接至心脏替代治疗率显著高于≤14天组。
  • 超14天支持者多为年轻、HF-CS、左室扩大患者。

核心结论

  • Impella 5.5超过FDA批准的14天支持时限仍可获得高比例良好结局,尤其作为桥接至心脏替代治疗。

研究设计与样本

  • 多中心注册研究,纳入2022-2024年34个国际中心连续HF或MI相关心源性休克患者,比较Impella 5.5支持>14天与≤14天的基线特征及院内结局。

主要发现

  • 927例中381例支持>14天,中位支持时间23.9天(IQR 21.2),≤14天组为7.1天(IQR 5.7)。
  • >14天组平均年龄57岁 vs 61岁(p<0.001),HF-CS比例78% vs 61%(p<0.001),LVEDD 6.4 vs 5.9 cm(p=0.002),CKD 38% vs 30%(p=0.03)。
  • 未调整生存率>14天组80% vs 68%(p<0.001),桥接至HRT率58% vs 38%(p<0.001)。
  • 严重不良事件发生率19.1%,MI-CS且支持≤14天者最高;>14天组75%获良好结局,严重不良事件率不随支持时间延长线性增加。

临床怎么用

  • 对需要延长机械循环支持过渡至心脏替代治疗的患者,Impella 5.5超14天使用可能获益,但需个体化评估并进一步前瞻性验证。

局限性

  • 注册研究设计,未调整混杂因素;延长支持时限需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Impella 5.5 (ABIOMED, Danvers, MA) is a micro-axial pump that is currently approved for up to 14 days of support in the United States. However, in clinical practice it is being used for longer durations of time, especially as a bridge to heart replacement therapies (HRT). We aimed to define patient characteristics and outcomes (mortality and serious adverse events/SAE) in patients supported on Impella 5.5 for >14 days in a large, multi-center registry. METHODS: The Cardiogenic Shock Working Group (CSWG) registry enrolling consecutive patients in heart failure (HF) or myocardial infarction related CS (MI-CS) from 34 international sites between 2022 and 2024 was analyzed. Patients supported with Impella 5.5 >14 days were compared to those supported for ≤14 days for baseline characteristics. In-hospital outcomes were further classified as ''favorable'' (heart recovery, successful bridge to HRT and discharged alive) or ''unfavorable'' (death, need for escalation to veno-arterial extracorporeal membrane oxygenation [VA-ECMO]). Predictors of favorable outcomes were assessed using uni- and multi-variable analysis. RESULTS: A total of 927 patients were supported on Impella 5.5 of whom 381 had the device for >14 days. Median time of support in the 2 groups (> or ≤14 days) was 23.9 [21.2] and 7.1 [IQR 5.7] days, respectively. Patients with Impella 5.5 >14 days were younger (mean age 57 vs 61 years, p < 0.001), more likely to have HF-CS vs MI-CS (78% vs 61%; p < 0.001) and have a dilated left ventricle (left ventricular end diastolic dimension [LVEDD] 6.4 vs 5.9 cm, p = 0.002) and chronic kidney disease (38% vs 30%, p = 0.03) as compared to those supported ≤14 days. Baseline Society for Cardiovascular Angiography and Interventions (SCAI) stage, lactate, and vital signs were not significantly different. Unadjusted survival was higher (80% vs 68%, p < 0.001) in those supported for >14 days, with a significantly higher HRT for those supported for >14 days, compared to the ≤14 days cohort (58% vs 38%, p < 0.001). Less than a fourth (19.1%) had an SAE, with highest rates seen in MI-CS supported for ≤14 days. The majority (75%) of patients on support for >14 days had favorable outcomes with no linear increments in rates of SAE with prolonged duration of support. CONCLUSION: Patients supported with Impella 5.5 beyond the Food and Drug Administration (FDA) approved duration of 14 days had high rates of favorable outcomes, especially as bridge to HRT. Use of Impella 5.5 for longer durations needs to be further investigated in prospective studies.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Kanwar MK, Uriel N, Carnicelli A, et al. Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis. J Heart Lung Transplant. 2025. PMID: 40592372. doi:10.1016/j.healun.2025.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。